VANCOUVER, BC, Dec. 15, 2021 /CNW/ – MYND Life Sciences Inc. (“MYND” or the “Company“) (CSE: MYND) (OTC: MYNDF) is pleased to announce it has completed the National Phase filing of its Patent Cooperation Treaty (PCT) patent application, following on previously submitted provisional patent applications that describe: “A Method of Immune Modulation by Modulating a Specific Gene.


Previous articlePsychedelics and Substance Use Disorder: 4000 BCE to Present Day
Next articlePTSF89 – A Macro Dive Into Microdosing